Podcast: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer

This expert-led episode of Oncology Data Advisor TM, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. Listen now to earn free CME/NCPD!

STATEMENT OF NEED

An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 84% of cases are classified as non–small cell lung cancer (NSCLC) (ACS, 2022). Though new screening procedures have identified more lung cancers at an earlier stage, most patients are still diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management. Chemoimmunotherapy has significantly improved the overall survival of patients compared with chemotherapy alone, but challenges remain in its optimal use (Tuminello et al, 2022). This activity will help update learners regarding this rapidly changing field. Ticiana Leal, MD, and Beth Sandy, MSN, CRNP, will analyze the latest guidance on patient selection, efficacy, safety, and supportive care strategies for non–small cell lung cancer immunotherapy.

TARGET AUDIENCE

Oncologists, pulmonologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with NSCLC.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to
Identify patient selection criteria for immunotherapy in advanced NSCLC
Evaluate emerging efficacy and safety data on immunotherapy-based strategies for advanced NSCLC without driver mutations
Assess supportive care plans to control immune-mediated adverse events and optimize survivorship in patients with advanced NSCLC